A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma

Acta Ophthalmologica Scandinavica

Volumn 80, Issue 6, 2002, Pages 635-641

  Honrubia, F M ^a,d   Larsson, L I ^b   Spiegel, D ^c,d   Blomster, L ^d   Bruckner B ^d   Buisman, N ^d   Fossas, M ^d   de Graaf Kret, C ^d   Grundler A ^d   Gutierrez E ^d   Hamacher, T ^d   Hernandez Barahona J ^d   Hofmann, M ^d   Khalil, H ^d   Kunnecke A ^d   Lierow, R ^d   Lippitz, G ^d   Moreno, A ^d   Lopez Munoz D ^d   Munoz Negrete F ^d   Perez Salvador J L ^d   Riera, M ^d   Schaal, T ^d   Scherzer, M L ^d   de Sera, J ^d   Tenhunen, T ^d   Tarrus F ^d   van Tilburg, C ^d   Uusitalo, H ^d   Wagner, M ^d   more..

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b Pharmacia Corporation   (Sweden)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d NONE

Author keywords

Dorzolamide timolol; Intraocular pressure; Latanoprost; Open angle glaucoma; Treatment

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCARDEN; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; TIMOLOL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BLEPHARITIS; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; EPIPHORA; EYE BURNING; EYE IRRITATION; EYE PAIN; EYELID EDEMA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAOCULAR PRESSURE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA VEIN OCCLUSION; RETINOPATHY; SEBACEOUS GLAND DISEASE; TASTE DISORDER; TREATMENT FAILURE; VISUAL IMPAIRMENT; VITREOUS DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 0036909866     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2002.800615.x     Document Type: Article

References (29)

1. Alm A, Stjernschantz J & the Scandinavian Latanoprost Study Group (1995b): Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102: 1743-1752.
2. Alm A, Widengård I, Kjellgren D, Soderström M, Friström B, Heijl A & Stjernschantz J (1995a): Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 79: 12-16.
3. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S & Lindenmuth K (2000): Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9: 134-142.
4. Barnebey H & Kwok SY (2000): Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 22: 1204-1212.
5. Boyle JE, Ghosh K, Gieser DK, Adamsons IA & the Dorzolamide-Timolol Study Group (1998): A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 105: 1945-1951.
6. Bucci MG & the Italian Latanoprost Study Group (1999): Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicentre study in patients with open-angle glaucoma. J Glaucoma 8: 24-30.
7. Camras CB & the United States Latanoprost Study Group (1996a): Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicentre trial in the United States. Ophthalmology 103: 138-147.
8. Camras CB, Alm A, Watson P, Stjernschantz J & the Latanoprost Study Groups (1996b): Latanoprost, a prostaglandin analogue for glaucoma treatment. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 103: 1916-1924.
9. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA & the Dorzolamide-Timolol Combination Study Group (1998): A randomized trial in patients inadequately controlled with timolol alone, comparing the dorzolamide-timolol combination to monotherapy with timolol and dorzolamide. Ophthalmology 105: 1952-1959.
10. Collaborative Normal-Tension Glaucoma Study Group (1998): Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126: 487-497.
11. Emmerich K-H (2000): Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomized study. Graefe's Arch Clin Exp Ophthalmol 238: 19-23.
12. Garcia Sanchez J & the Spanish Latanoprost Study Group (2000): Efficacy and side-effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension - a 3-month randomized study. Eur J Ophthalmol 10: 198-204.
13. Grierson I, Cracknell KPB & Pfeiffer N (2001): The iris after prostanoid treatment. Curr Opin Ophthalmol 12: 112-118.
14. Hartenbaum D (1996): The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension. Clin Ther 18: 460-465.
15. Johnstone MA (1997): Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 124: 544-547.
16. Larsson L-I (2001): Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology 108: 1439-1444.
17. Mishima HK, Masuda K, Kitazawa Y, Azuma I & Araie M (1996): A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 114: 929-932.
18. Patel SC & Spaeth GL (1995): Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 26: 233-236.
19. Perfetti S, Varotto A, Massagrandi S, Pagliani F & Bonomi L (1998): Glaucoma and quality of the life. Acta Ophthalmol Scand 227: S52.
20. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF & McGorray S (1998): Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 105: 561-566.
21. Silver LH & the Brinzolamide Comfort Study Group (2000): Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution. Results from two multicentre comfort studies. Surv Ophthalmol 44: S141-S145.
22. 2a analogue. Adv Prostaglandin Thromboxane Leukot Res 23: 513-518.
23. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM & the Dorzolamide Additivity Study Group (1996): The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 193: 1283-1293.
24. 2a analogue, on aqueous humour dynamics in human eyes. Ophthalmology 100: 1297-1304.
25. Watson PG & the Latanoprost Study Group (1998): Latanoprost. Two years experience of its use in the United Kingdom. Ophthalmology 105: 82-87.
26. Watson P, Stjernschantz J & the Latanoprost Study Group (1996): A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103: 126-137.
27. Weinreb RN (1992): Compliance with medical treatments of glaucoma. J Glaucoma 1: 134-136.
28. Wistrand PJ, Stjernschantz J & Olsson K (1997): The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye colour. Surv Ophthalmol 41: S129-S138.
29. 2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 111: 1351-1358.